Table 2.
Association of Baseline Conditions and Monoclonal Antibody Treatment on Adverse Clinical Outcomes Within 30 Days of Test Confirmation of Coronavirus Disease 2019
| Characteristic | ED Visit or Hospitalization | ICU Admission | Death | |||
|---|---|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
| Age | 1.01 | (1.01–1.02) | 1.02 | (1.01–1.03) | 1.06 | (1.04–1.07) |
| Male sex | 1.43 | (1.26–1.63) | 1.50 | (1.27–1.89) | 1.56 | (1.15–2.11) |
| Non–African American race | 1.39 | (1.21–1.59) | 1.34 | (1.01–1.54) | 1.60 | (1.16–2.22) |
| BMI | 1.02 | (1.01–1.03) | 1.02 | (1.00–1.03) | 1.00 | (.98–1.03) |
| Past medical history | ||||||
| Hypertension | 1.04 | (.89–1.23) | 1.04 | (.79–1.37) | 1.02 | (.64–1.64) |
| Coronary artery disease | 1.03 | (.86–1.23) | 0.95 | (.75–1.21) | 0.97 | (.69–1.36) |
| Diabetes | 1.18 | (1.09–1.29) | 1.48 | (1.31–1.67) | 1.17 | (.98–1.40) |
| COPD | 1.33 | (1.15–1.53) | 2.12 | (1.67–2.71) | 2.45 | (1.73–3.46) |
| Chronic kidney disease | 1.14 | (1.05–1.23) | 1.52 | (1.23–1.86) | 2.07 | (1.53–2.81) |
| Cancer | 1.02 | (.97–1.08) | 1.17 | (1.05–1.30) | 1.32 | (1.14–1.53) |
| Immunocompromised | 1.43 | (1.10–1.89) | 1.02 | (.95–1.10) | 1.09 | (.99–1.21) |
| Specimen collection in ED | 1.39 | (.96–1.26) | 1.83 | (1.51–2.22) | 1.31 | (.96–1.77) |
| mAb treatment | 0.23 | (.15–.36) | 0.06 | (.01–.25) | 0.12 | (.03–.51) |
Bold text indicates odds ratios with 95% confidence intervals that do not include 1.
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ED, emergency department; ICU, intensive care unit; mAb, monoclonal antibody; OR, odds ratio.